Halophila stipulacea is a well-known invasive marine sea grass in the Mediterranean Sea. Having been introduced into the Mediterranean Sea via the Suez Channel, it is considered a Lessepsian migrant. Although, unlike other invasive marine seaweeds, it has not demonstrated serious negative impacts on indigenous species, it does have remarkable invasive properties. The present in-silico study reveals the biotechnological features of H. stipulacea by showing bioactive peptides from its rubisc/o protein. These are features such as antioxidant and hypolipideamic activities, dipeptidyl peptidase-IV and angiotensin converting enzyme inhibitions. The reported data open up new applications for such bioactive peptides in the field of pharmacy, medicine and also the food industry.

Aquarium originated marine green alga Caulerpa taxifolia was introduced into the Mediterranean Sea accidentally in 1984. This invasion has been negatively affecting the sub-littoral ecosystem of the Mediterranean. One of the important reasons for its success in the Mediterranean is its secondary toxic metabolite called caulerpenyne (CPN). Furthermore, CPN has anti-proliferative and apoptotic activities, therefore, CPN can be considered as a potential native source in cancer therapy. For that reason, modeling this metabolite might be of importance. Increase and decrease of the CPN level before reaching the critical level can be expressed by means of a queueing system in which the number of ‘customers' increases and decreases. In fact, production of CPN shows fluctuations for many environmental reasons, which allow us to apply queueing theory. In the present study, the expected time to reach the maximum caulerpenyne level was analyzed and evaluated using queueing theory.